Business Description
Australian Clinical Labs Ltd
ISIN : AU0000148496
Description
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.09 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 1.74 | |||||
| Debt-to-EBITDA | 1.82 | |||||
| Interest Coverage | 11.51 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.63 | |||||
| Beneish M-Score | -3.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.4 | |||||
| 3-Year EBITDA Growth Rate | -11.3 | |||||
| 3-Year EPS without NRI Growth Rate | -32.9 | |||||
| 3-Year FCF Growth Rate | -6.8 | |||||
| 3-Year Book Growth Rate | 29.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.42 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.17 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.22 | |||||
| 9-Day RSI | 44.22 | |||||
| 14-Day RSI | 45.76 | |||||
| 6-1 Month Momentum % | 33.59 | |||||
| 12-1 Month Momentum % | 24.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.64 | |||||
| Quick Ratio | 0.56 | |||||
| Cash Ratio | 0.13 | |||||
| Days Inventory | 49.68 | |||||
| Days Sales Outstanding | 33.29 | |||||
| Days Payable | 87.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.46 | |||||
| Dividend Payout Ratio | 0.75 | |||||
| Forward Dividend Yield % | 5.19 | |||||
| 5-Year Yield-on-Cost % | 3.46 | |||||
| Shareholder Yield % | 3.71 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.7 | |||||
| Operating Margin % | 8.11 | |||||
| Net Margin % | 3.47 | |||||
| FCF Margin % | 22.2 | |||||
| ROE % | 13.95 | |||||
| ROA % | 4.09 | |||||
| ROIC % | 6.11 | |||||
| ROC (Joel Greenblatt) % | 14.32 | |||||
| ROCE % | 10.57 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.92 | |||||
| Forward PE Ratio | 18.07 | |||||
| PE Ratio without NRI | 26.09 | |||||
| Price-to-Owner-Earnings | 4.89 | |||||
| PS Ratio | 1.01 | |||||
| PB Ratio | 3.94 | |||||
| Price-to-Tangible-Book | 57.83 | |||||
| Price-to-Free-Cash-Flow | 4.54 | |||||
| Price-to-Operating-Cash-Flow | 4.36 | |||||
| EV-to-EBIT | 23.85 | |||||
| EV-to-Forward-EBIT | 10.24 | |||||
| EV-to-EBITDA | 5.8 | |||||
| EV-to-Forward-EBITDA | 4.06 | |||||
| EV-to-Revenue | 1.43 | |||||
| EV-to-Forward-Revenue | 1.34 | |||||
| EV-to-FCF | 6.42 | |||||
| Price-to-Graham-Number | 8.07 | |||||
| Earnings Yield (Greenblatt) % | 4.19 | |||||
| FCF Yield % | 21.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Australian Clinical Labs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 689.728 | ||
| EPS (TTM) (A$) | 0.12 | ||
| Beta | 1.5 | ||
| Volatility % | 44.26 | ||
| 14-Day RSI | 45.76 | ||
| 14-Day ATR (A$) | 0.11278 | ||
| 20-Day SMA (A$) | 3.531 | ||
| 12-1 Month Momentum % | 24.11 | ||
| 52-Week Range (A$) | 2.14 - 3.855 | ||
| Shares Outstanding (Mil) | 200.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Australian Clinical Labs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Australian Clinical Labs Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Australian Clinical Labs Ltd Frequently Asked Questions
What is Australian Clinical Labs Ltd(ASX:ACL)'s stock price today?
The current price of ASX:ACL is A$3.47. The 52 week high of ASX:ACL is A$3.86 and 52 week low is A$2.14.
When is next earnings date of Australian Clinical Labs Ltd(ASX:ACL)?
The next earnings date of Australian Clinical Labs Ltd(ASX:ACL) is 2025-02-28 Est..
Does Australian Clinical Labs Ltd(ASX:ACL) pay dividends? If so, how much?
The Dividend Yield %  of Australian Clinical Labs Ltd(ASX:ACL) is 3.46% (As of Today), Highest Dividend Payout Ratio of Australian Clinical Labs Ltd(ASX:ACL) was 2.68. The lowest was 0.14. And the median was 0.83. The  Forward Dividend Yield % of Australian Clinical Labs Ltd(ASX:ACL) is 5.19%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers